Pulmatrix Inc (PULM)

[riskon]

Part 3 of the Phase 1/1b Clinical Trial of Pulmazole (Pur1900) to show clinical effectiveness. Positive news after a positive part 1,2 will be significant as it will signify and create value from being a better direct competition to the $2B Sporanox, and a market void as a platform to deliver a new method of inhaler technology w/ any drug (licensing iSperse Technology). Partnerships & Trials w/ China [huge demand] said to be shortly thereafter potentially. No reason to think it won't be effective based upon previous results and U.S.'s favorable rulings and fast-tracking.

By Mid-July -- so likely by 7/16 Pre-Market based upon timing.

https://ir.pulmatrix.com/2018-06-25-Pulmatrix-Announces-Positive-Top-Line-Results-from-Parts-1-and-2-of-the-3-Part-Phase-1-1b-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole